Clinical Trials Using Atezolizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Atezolizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 108

  • Vemurafenib, Cobimetinib, and Atezolizumab in Treating Patients with High-Risk Stage III Melanoma

    This early phase I pilot trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating patients with high-risk stage III melanoma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib, cobimetinib, and atezolizumab may work better in treating high-risk stage III melanoma.
    Location: 3 locations

  • A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline / Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

    This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
    Location: 3 locations

  • Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases

    This phase II trial studies how well atezolizumab works when given together with pertuzumab and high-dose trastuzumab in treating patients with HER2-positive breast cancer that has spread to the central nervous system from other parts of the body. Immunotherapy with monoclonal antibodies, such as atezolizumab and pertuzumab, may help the body’s immune system attack the cancer, may induce changes in body’s immune system, and may interfere with the ability of tumor cells to grow and spread. Trastuzumab is a form of “targeted therapy” because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body’s immune system. Giving atezolizumab, pertuzumab, and trastuzumab may work better in treating patients with breast cancer compared to pertuzumab and trastuzumab.
    Location: 3 locations

  • Atezolizumab, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER2 Positive Breast Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

    This phase IIa trial studies the side effects of atezolizumab when given together with paclitaxel, trastuzumab, and pertuzumab and to see how well it works in treating patients with HER2 positive breast cancer that has come back at or near the same place as the original (primary) tumor, has spread to other places in the body, or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as atezolizumab, trastuzumab, and pertuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, paclitaxel, trastuzumab, and pertuzumab may work better in treating patients with HER2 positive breast cancer.
    Location: 3 locations

  • Atezolizumab in Treating Patients with Cancer following Adoptive Cell Transfer

    This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 5 locations

  • A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and / or Other Treatments in Participants With Solid Tumors

    This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.
    Location: 3 locations

  • A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and / or Refractory Acute Myeloid Leukemia

    This Phase Ib study is designed to evaluate the safety and pharmacokinetics of atezolizumab when given in combination with Hu5F9-F4 to patients with relapsed or refractory (R / R) acute myeloid leukemia (AML).
    Location: 3 locations

  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
    Location: 3 locations

  • Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

    This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.
    Location: 2 locations

  • Stereotactic Body Radiation Therapy and Atezolizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical Cancer

    This phase II trial studies how well stereotactic body radiation therapy (SBRT) and atezolizumab works in treating patients with cervical cancer that has come back, persistent, or has spread to other places in the body. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SBRT and atezolizumab may work better in treating patients with cervical cancer.
    Location: 2 locations

  • Atezolizumab and Stereotactic Radiation in Treating Participants with Stage IV Triple Negative Breast Cancer and Brain Metastasis

    This phase II trial studies how well atezolizumab and stereotactic radiosurgery work in treating participants with stage IV triple negative breast cancer that has spread to the brain. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic radiation is a specialized radiation therapy that uses many precisely focused radiation beams to treat tumors with minimal impact on the surrounding healthy tissue. Giving atezolizumab and stereotactic radiation may work better in treating participant with triple negative breast cancer.
    Location: 2 locations

  • A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

    This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: the first-line (1L) cohort will consist of patients who have not received any systemic therapy for their disease and the second-line (2L) cohort will consist of patients who progressed during or after receiving a platinum-containing regimen and a PD-L1 / PD-1 checkpoint inhibitor treatment. In each cohort, eligible patients will be assigned to one of several treatment arms.
    Location: 2 locations

  • Atezolizumab, Entinostat, and Bevacizumab in Treating Patients with Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of entinostat when given together with atezolizumab and bevacizumab and how well they work in treating patients with kidney cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab, entinostat, and bevacizumab may work better in treating patients with kidney cancer.
    Location: 3 locations

  • Atezolizumab in Treating Patients with Non-metastatic Bladder Cancer

    This phase II trial studies the best dose of atezolizumab and how well it works in treating patients with bladder cancer that has not spread to other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 3 locations

  • A Vaccine (Personalized Cancer Vaccine RO7198457), Atezolizumab, and Combination Chemotherapy for the Treatment of Resectable Stage I-III Pancreatic Cancer

    This phase I trial studies how well a personalized cancer vaccine RO7198457 works in combination with atezolizumab and fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin in treating patients with stage I-III pancreatic cancer that has been removed by surgery (resected). The personalized cancer vaccine RO7198457 is a vaccine that is customized according to changes (mutations) in a patient's tumor cells so that it can be recognized by the immune system and target the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving personalized cancer vaccine RO7198457, atezolizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin may work better compared to chemotherapy alone in treating patients with pancreatic cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Immunotherapy (Atezolizumab and Varlilumab) in Combination with Radiation Therapy for the Treatment of Advanced Unresectable Non-small Cell Lung Cancer

    This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation therapy in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies such as atezolizumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies such as varlilumab may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving atezolizumab, varlilumab, and radiation therapy may increase the amount of time the disease is not active or does not spread to another part of the body.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Derazantinib and Atezolizumab in Patients With Urothelial Cancer

    The purpose of this study is to evaluate efficacy of derazantinib single-agent or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.
    Location: Yale University, New Haven, Connecticut

  • Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

    MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC).
    Location: 2 locations

  • A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

    A Phase Ib / II, open-label, multicenter, randomized, umbrella study in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status).
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

    A Phase 1 / 2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Atezolizumab with or without Enzalutamide in Treating Men with Localized Prostate Cancer before Radical Prostatectomy

    This phase II trial studies how well atezolizumab works alone or in combination with enzalutamide in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgens made by the body. Giving atezolizumab in combination with enzalutamide may work better in treating prostate cancer.
    Location: 2 locations

  • Carboplatin, Pemetrexed, and Bevacizumab with or without Atezolizumab for the Treatment of Stage IV Non-squamous Non-small Cell Lung Cancer

    This phase II trial studies if the combination therapy of carboplatin, pemetrexed, bevacizumab (Avastin) and atezolizumab (Tecentriq) is better at controlling disease progression in non-squamous non-small cell lung cancer (NSCLC) patients who have never smoked or have a sensitizing EGFR mutation as compared to patients treated with the combination therapy without Tecentriq. Drugs used in chemotherapy, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a monoclonal antibody that binds to a protein called vascular endothelial growth factor (VEGF). This may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving carboplatin, pemetrexed, bevacizumab, and atezolizumab may work better in treating patients with non-squamous non-small cell lung cancer that have EGFR mutation or do not have EGFR mutation but have never smoked, compared to carboplatin, pemetrexed, and bevacizumab without atezolizumab.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients with Esophageal or Gastroesophageal Cancer

    This early phase I trial studies how well atezolizumab in combination with oxaliplatin and fluorouracil works in treating patients with esophageal or gastroesophageal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, oxaliplatin, and fluorouracil may work better in treating patients with esophageal or gastroesophageal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Atezolizumab, Carboplatin, and Gemcitabine Hydrochloride in Treating Patients with Metastatic or Unresectable and Locally Advanced Urothelial Carcinoma

    This phase II trial studies how well atezolizumab, carboplatin, and gemcitabine hydrochloride work in treating patients with urothelial carcinoma that has spread to other places in the body or cannot be removed by surgery and has spread to nearby tissue or lymph nodes. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, carboplatin, and gemcitabine hydrochloride may work better in treating patients with urothelial carcinoma.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Atezolizumab with or without Other Immune Modulating-Agents in Treating Patients with Stage III or IV Head and Neck Squamous Cell Cancer

    This phase II trial studies how well atezolizumab works in treating patients with stage III or IV head and neck squamous cell cancer, and if adding atezolizumab to the standard-of-care treatment (surgical resection followed by radiation or chemoradiation) decreases the occurrence of cancer relapse. Immunotherapy with monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California